Vitamin D3 Supplementation for Women with Symptomatic Uterine Fibroid and Vitamin D Deficiency

Study start date: February 20, 2025

Inclusion Criteria: .Women aged between 18-50 not currently pregnant, lactating, or planning to conceive during the study period. * Women with a confirmed diagnosis of uterine fibroids (leiomyoma) through ultrasound. * Serum 25-hydroxyvitamin D \[25(OH)D\] levels below 20 ng/mL (indicating vitamin D deficiency). * Presence of symptoms associated with uterine fibroid, such as menorrhagia (heavy menstrual bleeding), or bulk-related symptoms (e.g., urinary frequency). * Participants should be generally healthy, with no history of other chronic illnesses that could affect the study's outcomes (e.g., autoimmune diseases, cancers, severe liver or kidney diseases). * Willingness to provide written informed consent for participation in the study. * No current use of hormonal therapy, other vitamin D supplements, or medications known to influence calcium metabolism or uterine fibroid growth (e.g., GnRH agonists, anti-estrogens). * Participants must be willing and able to adhere to the study protocol, including attending follow-up visits and completing any required assessments or tests. Exclusion Criteria: * Women younger than 18 or older than 50 years. * Serum 25-hydroxyvitamin D \[25(OH)D\] levels of 20 ng/mL or higher. * Women without a confirmed diagnosis of uterine fibroids (leiomyoma) through imaging. * Pregnant or breastfeeding women, or those planning to conceive during the study period. * Presence of chronic illnesses such as autoimmune diseases, cancers, or severe liver or kidney disease that could interfere with the study's outcomes. * Current or recent use of hormonal therapy, other vitamin D supplements, or medications that affect calcium metabolism or uterine fibroid growth (e.g., GnRH agonists, anti-estrogens). * Women who have undergone surgical interventions (e.g., myomectomy, hysterectomy) or other medical treatments specifically for uterine fibroid within the past 6 months. * Women with conditions like hyperparathyroidism or calcium disorders that might affect vitamin D metabolism or fibroid growth.